



## Intellia Therapeutics to Present at September Healthcare Investor Conferences

August 27, 2018

CAMBRIDGE, Mass., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will participate in the following upcoming healthcare conferences in September:

### **Tuesday, September 4, 2018**

#### **B. Riley FBR Healthcare Conference**

Panel: A Beginner's Guide to Gene Therapy

Location: New York, NY

Time: 12:50pm ET

### **Wednesday, September 5, 2018**

#### **Citi Biotech Conference**

Panel: Gene Editing

Location: Boston, Massachusetts

Time: 1:15pm ET

### **Thursday, September 6, 2018**

#### **Wells Fargo Healthcare Conference**

Location: Boston, Massachusetts

Time: 3:05pm ET

### **Thursday, September 27, 2018**

#### **Jefferies Gene Therapy Summit**

Location: New York, NY

A live webcast of Intellia's participation on the panel at the Citi Biotech Conference and presentation at the Wells Fargo Healthcare Conference will be accessible through the Events and Presentations page of the Investor Relations section of the company's website at [www.intelliatx.com](http://www.intelliatx.com). To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Intellia's website for approximately 14 days following each conference.

### **About Intellia Therapeutics**

Intellia Therapeutics is a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases by replacing patients' diseased cells. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at [intelliatx.com](http://intelliatx.com) and follow us on Twitter @intelliatweets.

### **Investor Contact:**

Lindsey Trickett

Vice President, Investor Relations

+1 857-285-6211

[lindsey.trickett@intelliatx.com](mailto:lindsey.trickett@intelliatx.com)

### **Media Contact:**

Jennifer Mound Smoter

Senior Vice President, External Affairs & Communications

+1 857-706-1071

[jenn.smoter@intelliatx.com](mailto:jenn.smoter@intelliatx.com)

